An R package UnifiedDoseFinding for continuous and ordinal outcomes in Phase I dose-finding trials

다국어 초록 (Multilingual Abstract)

Phase I dose-finding trials are essential in drug development. By finding the maximum tolerated dose (MTD) of a new drug or treatment, a Phase I trial establishes the recommended doses for later-phase testing.
The primary toxicity endpoint of interest is often a binary variable, which describes an event of a patient who experiences dose-limiting toxicity.
However, there is a growing interest in dose-finding studies regarding non-binary outcomes, defined by either the weighted sum of rates of various toxicity grades or a continuous outcome.
Although several novel methods have been proposed in the literature, accessible software is still lacking to implement these methods.
This study introduces a newly developed R package, UnifiedDoseFinding, which implements three phase I dose-finding methods with non-binary outcomes (Quasi- and Robust Quasi-CRM designs by Yuan it et al. (2007) and Pan it et al. (2014), gBOIN design by Mu it et al.(2019), and by a method by Ivanova and Kim (2009)). For each of the methods, UnifiedDoseFinding provides corresponding functions that begin with next_ that determines the dose for the next cohort of patients, select\_, which selects the MTD defined by the non-binary toxicity endpoint when the trial is completed, and get_oc, which obtains the operating characteristics.
Three real examples are provided to help practitioners use these methods. The R package UnifiedDoseFinding, which is accessible in R CRAN, provides a user-friendly tool to facilitate the implementation of innovative dose-finding studies with nonbinary outcomes.

참고문헌 (Reference)

1 Yin J, "phase1RMD: An R package for repeated measures dose-finding designs with novel toxicity and efficacy endpoints" 16 : e0256391-, 2021

2 Mu R, "gBOIN : a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points" 68 : 289-308, 2019

3 Frankel PH, "Untenable dosing : A common pitfall of modern DLT-targeting Phase I designs in oncology" 44 : 100583-, 2020

4 Lee SM, "Toxicity burden score : a novel approach to summarize multiple toxic effects" 3 : 537-541, 2012

5 Yuan Z, "The continual reassessment method for multiple toxicity grades : a bayesian Quasi-likelihood approach" 63 : 173-179, 2007

6 Pan H, "The continual reassessment method for multiple toxicity grades : a Bayesian model selection approach" 9 : e98147-, 2014

7 Meter EMV, "Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading" 30 : 2070-2080, 2011

8 Friedman HS, "Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma" 16 : 3570-3575, 1998

9 Dent SF, "Phase I trial design : are new methodologies being put into practice?" 7 : 561-566, 1996

10 Plummer R, "Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors" 14 : 7917-7923, 2008

11 Brahmer JR, "Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates" 8 : 3167-, 2010

12 Muenz D, "New statistical methods for phase I clinical trials of a single agent" The University of Michigan 2017

13 Zhang L, "Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I–III breast cancer: ER+/PR+, HER2-vs. triple-negative" 169 : 175-187, 2018

14 Fiteni F, "Health-related quality of life as an endpoint in oncology phase I trials : a systematic review" 19 : 1-8, 2019

15 Papke L, "Econometric methods for fractional response variables with an application to 401(k) plan participation rates" 11 : 619-632, 1996

16 Ezzalfani M, "Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities" 32 : 2728-2746, 2013

17 Bekele BN, "Dose-finding based on multiple toxicities in a soft tissue sarcoma trial" 99 : 26-35, 2004

18 Ivanova A, "Dose finding for continuous and ordinal outcomes with a monotone objective function : a unified approach" 65 : 307-315, 2009

19 Le Tourneau C, "Dose escalation methods in phase I cancer clinical trials" 101 : 708-720, 2009

20 Storer BE, "Design and analysis of Phase I clinical trials" 45 : 925-937, 1989

21 Paoletti X, "Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents : results of a DLT-TARGETT international survey" 50 : 2050-2056, 2014

22 O’Quigley J, "Continual reassessment method : A practical design for Phase I clinical trials in cancer" 46 : 33-48, 1990

23 National Cancer Institute: CTEP, "Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0"

24 Liu S, "Bayesian optimal interval designs for phase I clinical trials" 64 : 507-523, 2015

25 Yin G, "Bayesian model averaging continual reassessment method in Phase I clinical trials" 104 : 954-968, 2009

26 Meille C, "Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanismbased PK/PD model" 77 : CT154-, 2017